Dexamethasone can attenuate the inammatory response in asthma via regulation of the lncH19/miR-324-3p cascade

Objective: To investigate lncRNAs and their roles in regulating the inammatory response under treatment of Dexamethasone (Dex) in asthma. Methods: IL-1 beta (10 ng/ml) and LPS (1 μg/ml) was used to induce an inammatory cell model with A549 cells, and the results showed that IL-1 beta performed better against LPS. Dex with different concentration was used to attenuate inammation by IL-1 beta, and its effect was assessed by RT-PCR to detect the inammatory related mRNA, including IKbeta-alpha, IKKbeta, IL-6, IL-8, and TNF-alpha and ELISA to detect the inammatory cytokines TNF-alpha, IL-6 and IL-8. RT-PCR was used to quantify levels of lncRNAs, including lncMALAT1, lncHotair, lncH19, and lncNeat1. lncH19 was most closely correlated with the inammatory response, which was induced by IL-1beta and attenuated by Dex, Among the lncRNAs, the level of lncH19 exhibited the highest increase following treatment with 1 μM and 10 μM Dex. Therefore, lncH19 was selected for further function study. lncH19 expression was inhibited by shRNA transduced by lentivirus. Cell assays for cell proliferation and apoptosis as well as RT-PCR, western blot, and ELISA for inammatory related genes were conducted to conrm the functions of lncH19. Predicted target miRNAs of lncH19 included the following: hsa-miR-346, hsa-miR-324-3p, hsa-miR-18a-3p, hsa-miR-18b-5p, hsa-miR-146b-3p, hsa-miR-19b-3p, and hsa-miR-19a-3p. Following estimation by RT-PCR, hsa-miR-346, hsa-miR-18a-3p, hsa-miR-324-3p showed consistent patterns in A549 NC and A549 shlncH19. miRNA inhibitor was transfected into A549 NC and A549 shlncH19 cells, and expression levels were determined by RT-PCR. hsa-miR-324-3p was inhibited the most relative to hsa-miR-346 and hsa-miR-18a-3p and was subjected to further function study. RT-PCR, ELISA and Western Blot for inammatory related genes detection were conducted to validate the functions of the target hsa-miR-324-3p. Results: Dex with 1μM and 10 μM were shown to be effective in attenuating the inammatory response. During this process, lncH19 signicantly increased in expression (P < 0.05). Dex with 1μM was for further study. Under IL-1 beta treatment with or without Dex, the inhibition of lncH19 lead to an increase cell proliferation, a decrease in cell apoptosis, an increase in the protein level of inammatory-related genes, and the phosphorylation of P65, ICAM-1, VCAM-1, and inammatory cytokines. Following prediction of the targets of lncH19 and validation by RT-PCR, miR-346, miR-18a-3p, and miR-324-3p were found to be negatively correlated to lncH19. Additionally, Dex increased the expression of lncH19, but the expression of the aforementioned miRNAs was reduced. Among miRNAs, miR-324-3p was the most markedly down-regulated following treatment of miRNA inhibitors. The MTS assay and cell apoptosis assay showed that the miR-324-3p inhibitor inhibited cell proliferation and induced cell apoptosis, thereby signicantly attenuating the inammatory response, which reversed the effect of lncH19 in regulating cell proliferation and the secretion of inammatory cytokines (P < 0.05). Therefore, lncH19 might regulate miR-324-3p during Dex treatment in inammatory response of asthma. Conclusion: Dex can attenuate the inammatory response in asthma via regulation of the lncH19/miR-324-3p cascade. The results showed that lncH19 was most closely correlated with symptoms of inammation, as its expression decreased following addition of IL-1beta to cells but increased following supplementation of Dex. The expression of lncH19 was negatively correlated with miR-324-3p. We showed that Dex attenuates the inammatory effect by targeting a cascade involving lncH19 and miR-324-3p.

Increased in ammatory cytokines in the airway epithelium, such as IL-8, IL-1 beta, and tumor necrosis factor-alpha (TNF-alpha), were also observed in asthma [4,5]. These in ammatory cytokines are involved in inducing, prolonging and amplifying the in ammatory response by promoting the growth, proliferation and differentiation of eosinophils, promoting the generation of allergy-speci c immunoglobulin E (IgE), and inducing AHR. Therefore, the in ammatory response is an important symptom associated with asthma. Inhaled corticosteroids are commonly used medicine to treat asthma [6]. WILSON, S. J. found that some of the therapeutic e cacy of inhaled corticosteroids was mediated through inhibition of NF-kappaB-regulated gene expression [7]. NF-kappaB is a transcription factor regulating many of the cytokine and adhesion molecule genes expressed in allergic in ammation, cytokine including colony-stimulating factor and TNF-alpha, adhesion molecules including intercellular adhesion molecule (ICAM)-1 vascular cell adhesion molecule-1 (VCAM-1) [7]. Dexamethasone (Dex) is representative of synthetic corticosteroids [6]. Epithelial cells play an active role in in ammation by the production of cytokines and other mediators and may, therefore represent an important site of glucocorticoid action [8]. A549 is alveolar type-II adenocarcinoma cell line, because it show physical characteristics in common with human bronchial epithelial cell, many studies use this cell to study the mechanism of asthma [9][10][11]. The in ammatory cell model of asthma were induced by IL-1 beta and lipopolysaccharides(LPS) in this study with reference to previous studies [11][12][13].
Long non-coding RNAs (lncRNAs) are newly discovered RNAs, which are de ned as RNA molecules with lengths that exceed 200 nt. lncRNAs are involved in many biological processes, such as cell growth, differentiation, the cell cycle, and the progress and metastasis of cancer [14,15]. Much research has suggested that the abnormal expression of lncRNAs in human diseases is often due to the regulation of in ammatory cytokines, such as NF-kappaB [16]. Depending on their targets, lncRNAs can act as regulators for different biological processes. Therefore, we hypothesized that speci c lncRNAs might regulate the pathologic processes underlying asthma.
In this study, we targeted speci c lncRNAs that have been reported to be correlated with the in ammatory response to characterize their mechanistic roles in the in ammatory response in asthma. The in ammatory response was induced by IL-1 beta and LPS using previously described methods in A549 [11][12][13] and was then attenuated using Dex. We quanti ed changes in lncRNA expression during treatment of IL-1 beta with Dex in A549 cells. We also determined the functional roles of candidate lncRNAs in regulating the in ammatory response under treatment of Dex in asthma. Because the functions of lncRNAs are usually performed by targeting miRNAs, we identi ed the miRNA targets of lncRNAs as well as quanti ed their expression levels to characterize their functions.

Materials And Methods
Cell culture and treatment A549 were obtained from the Shanghai Cell Bank (Shanghai, China) and were cultured at 37℃ with 5% CO 2 . Cells were maintained on DMEM high-glucose culture medium with 10% fetal bovine serum (Gibco, USA). Cells were cultured, ampli ed, and passaged. After 3 days, cells were digested and pelleted by centrifuge. Cell morphology was observed using a light microscope and suspended at a concentration of 1 × 10 6 /ml. For in ammatory cell model, IL-1 beta (peprotech, USA) with 10ng/ml or LPS (sigma, USA ) with 1 μg/ml was added and reached for 8 hours, 16 hours, 24 hours. For the effect of Dex, Dex (sigma, USA ) with different concentration (10nM, 100nM, 1000nM, 10000nM) and IL-1 beta with 10ng/ml were added at the same time for 24 hours, for the functions of lncH19 and miR-324-3p, IL-1 beta with 10ng/ml and Dex with 1 μM were added at the same time, the cells and supernatant were harvested for further studies.

MTS assay
Cells were at a density of 1 × 10 6 /ml, and 100 μl/well were seeded into 96-well plates. IL-1 beta with 10ng/ml was applied to cells with or without Dex(1 μM) for 24 hours after transfection with or without miRNA inhibitor for 24 hours. Cells were examined at 1, 2, and 3 day. MTS was added. After 3 hours incubation, the optical density of the cells was detected at 490 nm.
Cell apoptosis assay 5 × 10 5 cells/well were seeded in 6-well plates overnight at 37℃. After treatment, cells were then pelleted and washed with PBS. 1× binding buffer was used to resuspend the cells, 5 μl 7-AAD staining solution and 5 μl of APCconjugated Annexin V were then added. Samples were tested using a FACSCalibur ow cytometer, and the percentage of apoptotic cells was measured.

Lentivirus preparation and infection
LncH19 sequence come from NCBI with the number NR_002196.2. The antisense sequence of lncH19 (5'-CGGCAAGAAGCGGGTCTGTTTCTTT-3') was synthesized and was cloned to the LV3 vector together with the inverted repeat sequence. The empty vector LV3 was used as a control. The lentivirus solution was prepared by Shanghai Majorbio, China. A549 cells were seeded in 96-well plates at a density of 3 × 10 4 cells/well. Virus solution was diluted in a 10× gradient at ve different concentrations with DMEM medium. The supernatant with culture medium was discarded from each well and supplemented with 100 μl of the virus solution at a different concentration in each well. Saline solution, instead of a virus solution, was used as a control. Cells were incubated at 37℃ with 5% CO 2 for 24 hours. The cell culture supernatant was replaced with fresh prepared 100 μl DMEM medium. Cells were then incubated for 72 hours. RT-PCR was performed to detect the expression of lncH19. miRNA inhibitor and the negative control were transfected using lipofetamine 3000 per the manufacturer's protocol (Thermo Fisher, USA).

ELISA assay to detect in ammatory cytokines
Cytokine concentrations in the cell culture supernate were determined using an ELISA kit for TNF-alpha, IL-6, and IL-8 (Cusabio, Wuhan, China). Brie y, 96-well plates were precoated with TNF-alpha-, IL-6-and IL-8-speci c human antibodies, and human TNF-alpha, IL-6, and IL-8 were used for the standard titration curve. Samples and standards were added and incubated for 120 minutes at 37℃. Biotin-labeled antibody was added and incubated for 60 minutes at 37℃. After washing three times, HRP-avidin was added, and samples were then incubated for 60 minutes at 37℃. Following three washes, TMB substrate was added, and samples were incubated for 25 minutes at 37℃ and protected from light. Stop solution was added, and photospectrometry was performed at 450 nm. mRNAs of the in ammatory related gene, including IKbeta-alpha, IKKbeta, IL-6, IL-8, and TNF-alpha, lncRNAs and miRNAs were veri ed by RT-PCR. M-MLV Reverse Transcriptase (Promega, USA) was used to synthesize cDNA. PCR reactions were prepared with GoTaq qPCR Master Mix (Promega, USA) and performed on an ABI 7500 system (Applied Biosystem, USA). The PCR program was as follows, 95℃ for 30 seconds, followed by 40 cycles of 95℃ for 5 seconds, and then 60℃ for 30 seconds. The housekeeping genes GAPDH and U6 were used to normalize expression levels. Primers are shown in Table 1.

Western blotting
Cells were lysed in 1% SDS lysis buffer. The BCA assay was used to determine protein concentrations. 10% SDS-PAGE was used to separate the protein. Protein was then transferred onto polyvinylidene uoride membranes. Nonfat milk in PBS was used to block the membrane at room temperature for 1 hours. The membrane was incubated overnight at 4℃ with primary antibody (p-P65 abcam (ab76302), P65 CST (8242), ICAM-1 Santa Cruz (sc-107), VCAM-1 Santa Cruz (sc-13160), GAPDH Transgen (HC301)). After several washes with PBS, membranes were incubated in blocking buffer with a secondary antibody coupled to horseradish peroxidase for 2 hours at room temperature. The complexes were formed on the membrane, and the membrane was then detected by ECLplus (Amersham Biosciences/GE Healthcare, Velizy, France).

Statistical analysis
The data are presented as the mean±standard deviation (SD), N=3. The unpaired Student's t-test and one-way analysis of variance (ANOVA) were used to analyze differences between two groups and multiple groups respectively. p< 0.05 was considered to indicate a statistically signi cant difference. GraphPad Prism software 7.0 was used for statistical analysis.

Dex attenuates the in ammatory response
To investigate the effect of Dex, we induced the in ammatory cell model with IL-1beta and LPS. A549 cells were applied for the assay and treated with IL-1beta at 10 ng/ml or LPS at 1 μg/ml in DMEM culture medium. Cells incubated with the reagents after 8, 16 and 24 hours were collected, and total RNA was isolated. RT-PCR was conducted to con rm the expression of the in ammatory related mRNA, including IKbeta-alpha, IKKbeta, IL-6, IL-8, and TNF-alpha. Generally, the results showed that IL-1beta performed better against LPS, as the mRNA levels of most of the in ammatory cytokines, aside from IL-6 and TNF-alpha, were signi cantly up-regulated at 8 hours; in addition, mRNA levels of all other cytokines were 2-to 4-fold greater at 24 hours (Fig 1A). The secretary cytokines in the cell culture medium, including IL-6, IL-8, and TNF-alpha, were determined by ELISA. The results were consistent in showing that IL-1beta was generally more effective, and the effect can be observed at 8 hours ( Fig 1B).
Therefore, we decided to use IL-1beta for 24 hours incubation to induce the asthma cell model.
Following the same principle, we used the cell model to characterize the effect of Dex. We incubated A549 cells with IL-1beta and Dex at different concentrations, ranging from 10 nM to 10000 nM at 24 hours. As before, RT-PCR and ELISA were used to evaluate the effect of Dex. mRNA levels of in ammatory related genes, including IKbeta-alpha, IKKbeta, IL-6, IL-8, and TNF-alpha, signi cantly increased following treatment with IL-1beta (P < 0.05). After adding Dex, the mRNA level was reduced to baseline levels, indicating that supplementation with Dex can attenuate the in ammatory response (Fig 2A). With respect to the secretary in ammatory cytokines, the concentration of IL-6, IL-8, and TNF-alpha increased signi cantly following treatment with IL-1beta relative to the control group. However, when cells were supplemented with Dex, the concentration of cytokines decreased, and Dex at both 1 uM and 10 uM signi cantly decreased in concentration ( Fig 2B). Therefore, these observations suggest that Dex plays a role in attenuating the in ammatory response.

Veri cation of the lncRNAs involved in in ammation attenuation
Based on our preliminary ndings, we targeted four lncRNAs, lncMALAT1, lncHotair, lncH19, and lncNeat1 to determine which of these lncRNAs are involved in processes underlying in ammation attenuation [17][18][19][20]. RT-PCR was conducted to determine lncRNA levels following treatment with IL-1 beta and Dex. The results show that the four candidate lncRNAs were down-regulated following treatment with IL-1 beta; however, lncRNA levels increased following supplementation with Dex (Fig 3). In general, lncRNA levels can be most clearly observed by the treatment of Dex at 1 μM and 10 μM (P < 0.05). Among the lncRNAs, the level of lncH19 exhibited the highest increase, approximately 2-fold, following treatment with 1 μM and 10 μM Dex. Therefore, lncH19 and Dex with 1 μM was selected for further function validation.
To verify the functions of lncH19, the corresponding shRNA was designed and infected to A549 cells by lentivirus.
The performance of the speci c shRNA was assessed by RT-PCR. Depending on the effect of the speci c shRNA, lncH19 expression decreased by 50% (Fig 4A). The cells were then treated with IL-1beta and Dex (1 μM) to investigate the effect of decreasing the expression of lncH19. Cell proliferation was assessed via the MTS assay.
Treatment of 1 μM Dex clearly inhibited cell proliferation, which might only be a side effect. When the expression of lncH19 was induced, cell proliferation increased relative to IL-1beta-treated cells lacking lncH19 inhibition with or without Dex (Fig 4B). We then further validated the functions of lncH19 via the owcytometry cell apoptosis assay.
Compared to the percentage of apoptotic cells with and without Dex treatment, apoptotic cells increased approximately 2-fold when Dex was applied. Cell apoptosis was inhibited and reduced by 30-50% relative to IL-1beta-treated samples lacking lncH19 inhibition with or without Dex (Fig 4C & 4D). Western blotting was conducted to determine the protein level of the genes that might be involved in the in ammatory response, including P65, p-P65, ICAM-1, and VCAM-1. The protein level of P65 did not change. For the rest of the genes, supplementation of Dex clearly decreased protein levels, but inhibition of lncH19 can also increase protein levels ( Fig 4E). Therefore, given the consistency of these results with those obtained via owcytometry and the MTS assay, the proteins p-P65, ICAM-1, and VCAM-1 are likely involved in the regulation of Dex. The cell culture supernatant was then collected, and the concentration of in ammatory cytokines, including IL-6, IL-8, and TNF-alpha was determined.
Cytokines decreased in concentration by approximately 50% following the addition of Dex. Moreover, the inhibition of lncH19 increased the concentration of in ammatory cytokines (Fig 4F). Therefore, Dex can attenuate the in ammatory response, and lncH19 plays an important role in in ammatory processes.

Validation of candidate miRNAs regulated by lncH19
Miranda v3.3a has been used to predict the target miRNAs of lncH19. miRNAs are presented in Table 2. Because expression of lncH19 was up-regulated following addition of Dex and because up-regulation of lncRNA tends to result in the down-regulation of miRNAs, we searched for down-regulated miRNAs following addition of Dex. miR-346, miR-18a-3p, and miR-324-3p were down-regulated and were therefore chosen for further validation (Fig 5). The corresponding miRNA inhibitors were designed and transfected to A549 cells. The performance of the inhibitors was assessed via RT-PCR. For both miR-18a-3p and miR-324-3p, the corresponding inhibitors clearly decreased the expression of miRNAs by ~50%. The inhibitor of miR-324-3p was signi cantly more effective relative to that of miR-18a-3p (Fig 6A). Therefore, we further investigated the functions of miR-324-3p and divided into four groups, the rst group, shNC+IL-1 beta+Dex+miRNA NC, abbreviated as NC+miRNA NC, the second group, shNC+IL-1 beta+Dex+miR-324-3p inhibitor, abbreviated as NC+miR-324-3p inhibitor, the third group, shlncH19+IL-1 beta+Dex+miRNA NC, abbreviated as shlncH19+miRNA NC, the fourth group, shlncH19+IL-1 beta+Dex+miR-324-3p inhibitor, abbreviated as shlncH19+miR-324-3p inhibitor. An MTS assay was conducted to assess cell proliferation.
By comparing the NC+miRNA NC group to NC+miR-324-3p inhibitor group, cell proliferation increased signi cantly at 72 hours (P < 0.05). When cells were infected with shRNA targeting lncH19, cell proliferation increased from an OD value of 1.5 to 2.0 relative to NC+miRNA NC group. Cell proliferation was lower in shlncH19+miR-324-3p inhibitor,group compare to shlncH19+miRNA NC (Fig 6B). Therefore, the evidence suggests that the expression of lncH19 inhibited cell proliferation, but the expression of miR-324-3p promoted cell proliferation. We also conducted cell apoptosis assays via owcytometry to determine the functions of miR-324-3p. The inhibition of lncH19 reduced apoptotic cells by ~30%, but inhibition of miR-324-3p clearly enhanced cell apoptosis relative to the NC+miRNA NC group (Fig 6C). mRNA levels of IkBalpha, Ikkbeta, IL-6, IL-8, and TNF-alpha were all up-regulated when lncH19 was inhibited but down-regulated when miR-324-3p was simultaneously inhibited relative to the NC+miRNA NC group ( Fig 6D). The cell culture supernatant was collected to determine the concentration of the cytokines IL-6, IL-8, and TNF-alpha. The concentration of cytokines increased signi cantly when lncH19 was inhibited by shRNA relative to the NC+miRNA NC group. However, the concentration of cytokines decreased signi cantly when the expression of miR-324-3p was simultaneously inhibited, indicating that the in ammatory response was suppressed (Fig 6E).
Western blotting was performed to determine the protein levels of in ammation-related genes, including p-P65, P65, ICAM-1, and VCAM-1. There was no signi cant change in the protein level of P65. Inhibition of lncH19 increased the protein levels of p-P65, ICAM-1, and VCAM-1 relative to the NC+miRNA NC group. However, protein levels were decreased when miR-324-3p was down-regulated by an inhibitor simultaneously. These ndings suggest that miR-324-3p is involved in lncH19 regulation. lncH19 might target and inhibit the expression of miR-324-3p and thereby regulate in ammation.

Discussion
In this study, IL-1beta-induced in ammatory A549 cells were attenuated by Dex to aid the study of lncRNAs. Initially, we targeted lncMALAT1, lncHotair, lncH19, and lncNeat1 and evaluated their expression levels. The results showed that lncH19 was most closely correlated with symptoms of in ammation, as its expression decreased following addition of IL-1beta to cells but increased following supplementation of Dex. The expression of lncH19 was negatively correlated with miR-324-3p. We showed that Dex attenuates the in ammatory effect by targeting a cascade involving lncH19 and miR-324-3p. lncH19 was discovered in the 11p15.5, H19/IGF2 locus [21]. lncH19 is highly expressed in the fetus but begins to be silenced after birth with its expression restricted to a few tissues, such as the mammary gland, uterus and adrenal gland [22]. Current research suggests that mutation of H19 in mouse zygotes causes prenatal lethality, indicating that H19 plays an important role in cell growth and development [23]. Therefore, our ndings are consistent with previous studies in that lncH19 is able to regulate cell activities, such as cell proliferation and cell apoptosis.
Previously, lncH19 has been shown to be correlated with the NF-kappaB pathway and is thus involved in the regulation of cell growth in multiple myeloma [16]. NF-kappaB is an important family of transcription factors involved in cell differentiation, apoptosis and immunity. Activation of the NF-kappaB pathway is involved in most cell activities in cancer transformation, such as the inhibition of cell differentiation and cell apoptosis, promotion of cell proliferation, angiogenesis and potential metastasis [24]. Currently, NF-kappaB also plays a role in the antiin ammatory effects in asthma [7,24], which suggests that it can provide an important pathway for lncH19 targets and regulate the processes underlying the in ammatory effects of asthma. Induction of the in ammatory response by IL-1 beta reduced the expression of lncH19. However, supplementation of Dex, which can attenuate the in ammatory response, signi cantly increased the expression of lncH19. The up-regulation of lncH19 expression is correlated with the attenuation of asthma; therefore, lncH19 is likely involved in anti-in ammatory processes associated with asthma. However, since lncRNAs usually inhibit targets, lncH19 might not directly target NF-kappaB. Therefore, we suspected that lncH19 targets and inhibits NF-kappaB and possibly other anti-in ammatory factors.
Further study of lncH19 revealed that the expression of miR-346, miR-17a-3p, and miR-324-3p were inhibited by lncH19 over-expression. Following detection of cell proliferation and cell apoptosis, inhibition of miR-324-3p revealed a highly signi cant correlation between cell proliferation and apoptosis. Therefore, we suspected that lncH19 regulates the in ammatory response by regulating miR-324-3p. miR-324-3p is a commonly expressed miRNA that regulates processes underlying cancer. The main target of miR-324-3p is SMAD7. According to Xu et al., the miR-324-3p/SMAD7 axis played a signi cant role in regulating cell growth and apoptosis in nasopharyngeal cancer [25]. Overexpression of SMAD7 is associated with the development of skin, pancreatic, lung, and colon cancer in the processes of cell growth and apoptosis [26]. Previous studies have shown that SMAD7 is correlated with the NF-kappaB pathway and therefore regulates the cell cycle in cancers [27]. In ammatory often changed the expression of p65, ICAM-1, and VCAM-1 [7]. Their expression levels can be used as indicators of the in ammatory response. Previous studies have also shown that p65 is associated with the activation of NF-kappaB [7]. By characterizing the expression of the aforementioned cytokines, we have con rmed that both lncH19 and miR-324-3p could be important factors in regulating the in ammatory response. Therefore, regulation of the in ammatory response might be achieved through the regulation of SMAD7/NF-kappaB pathways via a regulatory network between lncH19 and miR-324-3p in which lncH19 targets miR-324-3p. However, this proposed regulatory cascade requires further validation for future.
Our results have shown that Dex can attenuate the in ammatory response in asthma. The lncH19/miR-324-3p axis might play an important role in regulating the in ammatory response and thus cell proliferation and cell apoptosis.
Future studies should examine additional genes targets of the lncH19/miR-324-3p axis, including SMAD7 and NF-kappaB, to further elucidate the regulatory processes associated with the lncH19/miR-324-3p axis. Furthermore, the expression of lncH19/miR-324-3p should be quanti ed in animal model and actual asthma patients before and after the use of corticosteroids, the anti-in ammatory effect of Dex in asthma are regulated by the lncH19/miR324-3p pathways in animal model, the correlation between lncH19 and miR-324-3p expression changes in asthma is also what we would need to study in the future, as our hypothesized mechanism is based on a A549 cell model.
Data from actual patients are important for con rming the functions of the lncH19/miR-324-3p cascade and could contribute to asthma diagnoses as well as the development of therapeutic approaches to treat asthma. We can also search for possible ncRNAs by RNA-seq technology, because lncRNA may also interact with other ncRNAs.

Conclusion
In summary, we demonstrated here for the st time that Dex can attenuate the in ammatory response in asthma via regulation of the lncH19/miR-324-3p cascade. The present study indicated that lncH19/miR-324-3p cascade maybe contribute to asthma diagnoses as well as the development of therapeutic approaches to treat asthma in patient.     lncMALAT1, lncHotair, lncH19, and lncNeat1 were expressed less when A549 was treated by IL-1 beta (10 ng/ml) but were expressed more as the in ammatory response attenuated following application of Dex (1 μM), IL-1 beta and Dex added at the same time as the stimuli. Changes in lncH19 were the most pronounced. Data are presented as mean±SD. N=3.*P < 0.05, **P < 0.01. Dex: dexamethasone ,IL-1 beta: Interleukin-1 beta.

Figure 4
When lncH19 was inhibited while cells were treated with IL-1 beta (10 ng/ml) with or without Dex (1 μM) at the smae time, cell proliferation increased, cell apoptosis decreased, and the protein levels of in ammatory-related genes increased, promoting the phosphorylation of P65, ICAM-1, VCAM-1, and in ammatory cytokines. A. lncH19 expression was reduced, indicating that a lncH19-inhibited cell line was generated. B. Cell proliferation of A549 NC and A549 shlncH19 cells treated by IL-1 beta with or without Dex. C. Representative cell apoptosis diagram measured by owcytometry, upper left is fragment and damaged cell, upper right is late apoptosis and dead cell, lower left is normal cell of negative control, lower right is early apoptotic cell, the total of percent of apoptosis cells were caculated by the sum of the upper right and lower right. D. Percentage of apoptotic cells. E. Western blot for determining protein levels of in ammatory-related genes. F. ELISA for assessing levels of in ammatory cytokines.

Figure 5
RT-PCR was conducted to determine the level of miRNAs predicted to be targets of lncH19 with or without treatment of IL-1 beta (10 ng/ml) or IL-1 beta (10 ng/ml) and Dex (1 μM) were added at the same time; trends in the expression of miR-346, miR-18a-3p, and miR-324-3p were consistent in A549 NC and A549 shlncH19. Data are presented as mean±SD. N=3. **P < 0.01. Dex: dexamethasone, IL-1 beta: Interleukin-1 beta.

Figure 6
The attenuation of lncH19 by miR-324-3p was inhibited as the in ammatory response attenuated under treatment with IL-1 beta (10 ng/ml) and with Dex (1 μM) at the same time. A. Levels of candidate miRNAs determined by RT-PCR for examining the performance of the miRNA inhibitor. B. Cell proliferation determined by the MTS assay. C.